Treatment of low backpain with Unani medicine Majoon-e-Masihi

Comparative Clinical validation study of Unani pharmacopoeial formulation Majun Masihi vs Habb e suranjan in Waja al Qutn (Non-Specific Low Back Pain) - Not applicable

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070758

Enrollment

220

Registered

2024-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M545- Low back pain

Interventions

Intervention1: Maju¯n Masi¯hi¯: 5g (semisolid) to be taken orally twice a day with water after meals for 4 weeks Control Intervention1: Habbe- Suranjan: 3 tablet (500gm each) to be taken orally twice

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender. 2. Patients in the age group of 18-60 years 3. Clinically diagnosed patients with low back pain persisting for 4 weeks or more without any specific cause. 4. Patients with less than 40% disability by Oswestry Disability Index (ODI).

Exclusion criteria

Exclusion criteria: 1. Patients below 18 years and above 60 years of age. 2. BMI less than 18.5 and more than 30. 3. Recent low back injury. 4. Pregnant or lactating women. 5. Spinal pathology viz; severe or progressive motor weakness or central disc prolapsed, lumbar spondylolisthesis, lumbar radiculopathy, pending litigation (e.g., workplace injury), carcinoma 6. Patients receiving concomitant drug therapy with NSAID’s with wash out period of less than 7 days. 7. Patients having any systemic illness requiring long term treatment viz; hypertension, diabetes mellitus, rheumatoid arthritis. 8. Diagnosed cases of Pelvic inflammatory diseases (PID). 9. Patients with Psychosomatic conditions.

Design outcomes

Primary

Measure	Time frame
McGill Pain Questionnaire (MPQ), Oswestry Pain Disability index (ODI) also known as Oswestry low back pain disability scale and Quality of Life Scale (QOLS), will be used for the assessment of improvement.Timepoint: At baseline, 2nd and 4th week of the treatment	—

Secondary

Measure	Time frame
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and after 4 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ghazala.javed@gov.in9811810454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026